Literature DB >> 18204871

A first Portuguese epidemiological survey of fungaemia in a university hospital.

S Costa-de-Oliveira1, C Pina-Vaz, D Mendonça, A Gonçalves Rodrigues.   

Abstract

A prospective, observational study was conducted at the biggest Portuguese hospital, aiming to evaluate the epidemiology of bloodstream fungal infection. During a period of 12 months (2004), all yeasts isolated from the blood cultures of patients with fungaemia admitted at a university hospital of Porto were collected. Demographic and clinical data, as well as haematological and biochemical profiles, were registered. Antifungal susceptibility was evaluated. The incidence of fungaemia and nosocomial fungaemia were 2.7 and 2 per 1,000 hospital admissions, respectively. Blood strains from 117 patients were identified. Thirty-five percent of yeast isolates were Candida albicans, followed by C. parapsilosis (25.6%). The mortality rate associated with fungaemia was 39.3%; the highest values were found in patients with C. glabrata and C. tropicalis infection. Seventy-five percent of the fungaemia episodes were nosocomial, with 48% mortality; the main predisposing factors were parenteral nutrition, gastric protection with omeprazole, surgical drainage and the presence of central venous catheters (CVCs). Thrombocytopaenia, urinary catheter, gastrointestinal pathology and nosocomial fungaemia were independently associated with a poor outcome. Antifungal susceptibility testing showed high fluconazole resistance (15%), mostly in C. tropicalis. We observed a high incidence of nosocomial fungaemia with high mortality rates. Important predisposing factors were identified, deserving further investigation. Local surveillance is warranted to monitor the incidence of in vitro antifungal resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18204871     DOI: 10.1007/s10096-007-0448-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  37 in total

1.  Antifungal drug resistance.

Authors:  Juergen Loeffler; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

Review 2.  The role of antifungal susceptibility testing in the therapy of candidiasis.

Authors:  Duane R Hospenthal; Clinton K Murray; Michael G Rinaldi
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

3.  Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.

Authors:  Cidália Pina-Vaz; Acácio Gonçalves Rodrigues; Sofia Costa-de-Oliveira; Elisabete Ricardo; Per-Anders Mårdh
Journal:  J Antimicrob Chemother       Date:  2005-08-22       Impact factor: 5.790

4.  Epidemiology of candidemia.

Authors:  P Sandven
Journal:  Rev Iberoam Micol       Date:  2000-09       Impact factor: 1.044

5.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 6.  Resistance of human fungal pathogens to antifungal drugs.

Authors:  Dominique Sanglard
Journal:  Curr Opin Microbiol       Date:  2002-08       Impact factor: 7.934

7.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

8.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Management and outcome of bloodstream infections due to Candida species in England and Wales.

Authors:  C C Kibbler; S Seaton; R A Barnes; W R Gransden; R E Holliman; E M Johnson; J D Perry; D J Sullivan; J A Wilson
Journal:  J Hosp Infect       Date:  2003-05       Impact factor: 3.926

10.  Nosocomial bloodstream infections associated with Candida species in a Turkish University Hospital.

Authors:  Nur Yapar; Ulker Uysal; Mine Yucesoy; Nedim Cakir; Ayse Yuce
Journal:  Mycoses       Date:  2006-03       Impact factor: 4.377

View more
  25 in total

1.  Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Authors:  Emilia Cantón; Javier Pemán; Guillermo Quindós; Elena Eraso; Ilargi Miranda-Zapico; María Álvarez; Paloma Merino; Isolina Campos-Herrero; Francesc Marco; Elia Gomez G de la Pedrosa; Genoveva Yagüe; Remedios Guna; Carmen Rubio; Consuelo Miranda; Carmen Pazos; David Velasco
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Transcriptional profiling of azole-resistant Candida parapsilosis strains.

Authors:  A P Silva; I M Miranda; A Guida; J Synnott; R Rocha; R Silva; A Amorim; C Pina-Vaz; G Butler; A G Rodrigues
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

3.  Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series.

Authors:  A Spiliopoulou; G Dimitriou; E Jelastopulu; I Giannakopoulos; E D Anastassiou; Myrto Christofidou
Journal:  Mycopathologia       Date:  2011-11-11       Impact factor: 2.574

4.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

5.  Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.

Authors:  C J Seneviratne; S S W Wong; K Y Yuen; J H Meurman; P Pärnänen; M Vaara; L P Samaranayake
Journal:  Mycopathologia       Date:  2011-07-09       Impact factor: 2.574

6.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 7.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

9.  Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital.

Authors:  Ana P Silva; Isabel M Miranda; Carmen Lisboa; Cidália Pina-Vaz; Acácio G Rodrigues
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

10.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.